CNS Pharmaceuticals, Inc.
NASDAQ:CNSP
1.14 (USD) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Current Assets: | ||||||||
| Cash & Cash Equivalents
| 6.461 | 0.549 | 10.055 | 5.005 | 14.039 | 7.241 | 0.283 | 0.111 |
| Short Term Investments
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 6.461 | 0.549 | 10.055 | 5.005 | 14.039 | 7.241 | 0.283 | 0.111 |
| Net Receivables
| 0.883 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 1.315 | 1.042 | 5.018 | 2.473 | 1.456 | 0.653 | 0.305 | 0.052 |
| Total Current Assets
| 8.659 | 1.591 | 12.565 | 7.477 | 15.496 | 7.894 | 0.588 | 0.162 |
| Non-Current Assets: | ||||||||
| Property, Plant & Equipment, Net
| 0.006 | 0.005 | 0.006 | 0.016 | 0.023 | 0.018 | 0 | 0 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0.036 | 0.105 | 0.483 | 1.264 | 0.334 | -0 | 0.095 | 0 |
| Total Non-Current Assets
| 0.042 | 0.11 | 0.488 | 1.28 | 0.358 | 0.018 | 0.095 | 0 |
| Total Assets
| 8.701 | 1.701 | 13.053 | 8.757 | 15.853 | 7.912 | 0.683 | 0.162 |
| Liabilities & Equity: | ||||||||
| Current Liabilities: | ||||||||
| Account Payables
| 0 | 5.832 | 3.682 | 1.981 | 0.946 | 0.289 | 0.129 | 0.057 |
| Short Term Debt
| 0.326 | 0.301 | 0.41 | 0.388 | 0.439 | 0 | 0.317 | 0.122 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0.024 | 0 |
| Other Current Liabilities
| 2.198 | 0 | 0.828 | 0.225 | 0.52 | 0.022 | 0.787 | 0.041 |
| Total Current Liabilities
| 2.524 | 6.133 | 4.92 | 2.136 | 1.905 | 0.311 | 1.233 | 0.221 |
| Non-Current Liabilities: | ||||||||
| Long Term Debt
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Liabilities
| 0 | 0 | 4.092 | 0 | 0 | 0 | 0.446 | 0.179 |
| Total Liabilities
| 2.524 | 6.133 | 4.92 | 2.136 | 1.905 | 0.311 | 1.233 | 0.221 |
| Equity: | ||||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock
| 0.001 | 0.006 | 0.002 | 0.028 | 0.024 | 0.016 | 0.013 | 0.01 |
| Retained Earnings
| -84.425 | -69.567 | -50.716 | -34.983 | -20.946 | -11.488 | -7.611 | -0.219 |
| Accumulated Other Comprehensive Income/Loss
| 0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 |
| Other Total Stockholders Equity
| 90.6 | 65.129 | 58.847 | 41.604 | 34.87 | 19.073 | 7.049 | 0.151 |
| Total Shareholders Equity
| 6.177 | -4.432 | 8.133 | 6.622 | 13.948 | 7.601 | -0.549 | -0.059 |
| Total Equity
| 6.177 | -4.432 | 8.133 | 6.622 | 13.948 | 7.601 | -0.549 | -0.059 |
| Total Liabilities & Shareholders Equity
| 8.701 | 1.701 | 13.053 | 8.757 | 15.853 | 7.912 | 0.683 | 0.162 |